Selective estrogen receptor modulators (SERMs): A review of clinical data

Maturitas

Volumn 80, Issue 1, 2015, Pages 52-57

  Mirkin, Sebastian ^a   Pickar, James H ^b  

^a TherapeuticsMD   (United States)

^b Department of Medicine   (United States)

Author keywords

Breast cancer; Endometrial cancer; Menopause; Osteoporosis; SERM

Indexed keywords

ARZOXIFENE; BAZEDOXIFENE; LASOFOXIFENE; OSPEMIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RISK; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; ENDOMETRIAL THICKNESS; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; HUMAN; ISCHEMIC HEART DISEASE; OSTEOPENIA; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SPINE FRACTURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; UTERUS CANCER; VAGINA ATROPHY; VAGINA BLEEDING; BREAST NEOPLASMS; FEMALE; OSTEOPOROSIS, POSTMENOPAUSAL; WOMEN'S HEALTH;

BREAST NEOPLASMS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; WOMEN'S HEALTH;

EID: 84918559184     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2014.10.010     Document Type: Review

References (57)

1. K. Dahlman-Wright, V. Cavailles, and S.A. Fuqua International Union of Pharmacology. LXIV. Estrogen receptors Pharmacol Rev 58 2006 773 781
2. B.S. Katzenellenbogen, I. Choi, and R. Delage-Mourroux Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology J Steroid Biochem Mol Biol 74 2000 279 285
3. B.S. Komm, and S. Mirkin An overview of current and emerging SERMs J Steroid Biochem Mol Biol 2014 [Review, Epub ahead of print]
4. J.H. Pickar, T. MacNeil, and K. Ohleth SERMs: progress and future perspectives Maturitas 67 2010 129 138
5. R.M. O'Regan, and V.C. Jordan Tamoxifen to raloxifene and beyond Semin Oncol 28 2001 260 273
6. M. Sato, M.K. Rippy, and H.U. Bryant Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats FASEB J 10 1996 905 912
7. V.C. Jordan, and S.P. Robinson Species-specific pharmacology of antiestrogens: role of metabolism Fed Proc 46 1987 1870 1874
8. V.C. Jordan, and T. Jaspan Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response J Endocrinol 68 1976 453 460
9. P.Y. Maximov, T.M. Lee, and V.C. Jordan The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice Curr Clin Pharmacol 8 2013 35 155
10. Nolvadex [package insert] 2005 AstraZeneca Pharmaceuticals LP Wilmington, DE
11. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
12. B. Fisher, J.P. Costantino, and D.L. Wickerham Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 97 2005 1652 1662
13. J. Cuzick, J.F. Forbes, and I. Sestak Long-term results of tamoxifen prophylaxis for breast cancer - 96-month follow-up of the randomized IBIS-I trial J Natl Cancer Inst 99 2007 272 282
14. T.J. Powles Twenty-year follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial J Natl Cancer Inst 99 2007 283 290
15. U. Veronesi, P. Maisonneuve, and N. Rotmensz Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy J Natl Cancer Inst 99 2007 727 737
16. H. Staley, I. McCallum, and J. Bruce Postoperative tamoxifen for ductal carcinoma in situ Cochrane Database Syst Rev 10 October 2012 CD007847 10.1002/14651858.CD007847.pub2
17. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
18. Early Breast Cancer Trialists Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
19. C. Davies, P. Hongchao, and G. Jon Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 2013 805 816
20. H. Earl, R. Gray, D. Kerr, and M. Lee The optimal duration of tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom Clin Oncol (R Coll Radiol) 9 1997 141 143
21. S. Silverman, and C. Christiansen Individualizing osteoporosis therapy Osteoporos Int 23 2012 797 809
22. S.R. Cummings, S. Eckert, and K.A. Krueger The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation JAMA 281 1999 2189 2197
23. J.A. Cauley, L. Norton, and M.E. Lippman Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple Outcomes of Raloxifene Evaluation Breast Cancer Res Treat 65 2001 125 134
24. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 2006 2727 2741
25. V.G. Vogel, J.P. Costantino, and D.L. Wickerham Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer Cancer Prev Res (Phila, PA) 3 2010 696 706
26. E. Barrett-Connor, L. Mosca, and P. Collins Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 355 2006 125 137
27. B.S. Komm, Y.P. Kharode, P.V. Bodine, H.A. Harris, C.P. Miller, and C.R. Lyttle Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity Endocrinology 46 2005 3999 4008
28. J.V. Pinkerton, D.F. Archer, and W.H. Utian Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis Menopause 16 2009 1102 1108
29. D.F. Archer, J.V. Pinkerton, and W.H. Utian Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women Menopause 16 2009 1109 1115
30. L. Gennari Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy Expert Opin Pharmacother 10 2009 2209 2220
31. S.R. Cummings, K. Ensrud, and P.D. Delmas Lasofoxifene in postmenopausal women with osteoporosis N Engl J Med 362 2010 686 696
32. A.Z. LaCroix, T. Powles, C.K. Osborne PEARL Investigators Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women J Natl Cancer Inst 102 2010 1706 1715
33. P.N. Munster Arzoxifene: the development and clinical outcome of an ideal SERM Expert Opin Invest Drugs 15 2006 317 326
34. S.R. Cummings, M. McClung, and J.Y. Reginster Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women J Bone Miner Res 26 2011 397 404
35. Fareston [package insert]. Bridgewater, NJ: Prostrakan Inc.; 2012. Available at: http://www.fareston.com/uploads/documents/fareston-pi.pdf.
36. M. Gershanovich, A. Garin, and D. Baltina A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group Breast Cancer Res Treat 45 1997 251 262
37. D.F. Hayes, J.A. Van Zyl, and A. Hacking Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer J Clin Oncol 13 1995 2556 2566
38. S. Pyrhonen, R. Valavaara, and H. Modig Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study Br J Cancer 76 1997 270 277
39. T.M. Willson, J.D. Norris, and B.L. Wagner Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone Endocrinology 138 1997 3901 3911
40. L. Gennari, D. Merlotti, F. Valleggi, and R. Nuti Ospemifene use in postmenopausal women Expert Opin Invest Drugs 18 2009 839 849
41. E.M. Rutanen, J. Heikkinen, K. Halonen, J. Komi, R. Lammintausta, and O. Ylikorkala Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial Menopause 10 2003 433 439
42. J. Cuzick, T. Powles, and U. Veronesi Overview of the main outcomes in breast-cancer prevention trials Lancet 361 2003 296 300
43. J.V. Pinkerton, and S.R. Goldstein Endometrial safety: a key hurdle for selective estrogen receptor modulators in development Menopause 17 2010 642 653 10.1097/gme.0b013e3181c4f1d6
44. S. Mirkin, D.F. Archer, H.S. Taylor, J.H. Pickar, and B.S. Komm Differential effects of menopausal therapies on the endometrium Menopause 2014 [Epub ahead of print]
45. B. Fisher, J.P. Costantino, C.K. Redmond, E.R. Fisher, D.L. Wickerham, and W.M. Cronin Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J Natl Cancer Inst 86 1994 527 537
46. D.L. Wickerham, B. Fisher, and N. Wolmark Association of tamoxifen and uterine sarcoma J Clin Oncol 20 2002 2758 2760
47. A. DeMichele, A.B. Troxel, and J.A. Berlin Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study J Clin Oncol 26 2008 4151 4159
48. S. Mirkin, and B. Komm Tissue-selective estrogen complexes for postmenopausal women Maturitas 76 2013 213 220
49. G.D. Constantine, S.R. Goldstein, and D.F. Archer Endometrial safety of ospemifene: results of the phase 2/3 clinical development program Menopause June 2014 [Epub ahead of print]
50. E.G. Lufkin, S. Sarkar, and P.M. Kulkarni Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial Curr Med Res Opin 20 2004 351 357
51. ®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy Maturitas July 2014 [Epub ahead of print]
52. D. Portman, S. Palacios, R.E. Nappi, and A.O. Mueck Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial Maturitas 78 June (2) 2014 91 98 10.1016/j.maturitas.2014.02.015 [Epub 2014 Mar 12]
53. D.J. Portman, G.A. Bachmann, J.A. Simon Ospemifene Study Group Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy Menopause 20 June (6) 2013 623 630 10.1097/gme.0b013e318279ba64
54. J.V. Pinkerton, and F.Z. Stanczyk Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy Menopause 21 March (3) 2014 309 319 10.1097/GME.0b013e31829755ed
55. S. Mirkin, K.A. Ryan, A.B. Chandran, and B.S. Komm Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms Maturitas 77 January (1) 2014 24 31 10.1016/j.maturitas.2013.10.009 [Review]
56. B.S. Komm, and S. Mirkin Evolution of the tissue selective estrogen complex (TSEC) J Cell Physiol 228 July (7) 2013 1423 1427 10.1002/jcp.24324 [Review]
57. K. Ensrud, A. LaCroix, and J.R. Thompson Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial Circulation 122 2010 1716 1724 [Epub 2010 Oct 11]